Hepatitis B Virus Studies

HEPLISAV-B Breaks Immune Tolerance and Induces HBV Control via CD4 T Cell-Dependent Mechanisms in a Chronic Hepatitis B Mouse Model

HEPLISAV-B vaccine breaks HBV immune tolerance in a mouse model, inducing HBsAg clearance and anti-HBs immunity through CD4 T cell-dependent mechanisms.

Time-resolved proteomic analysis of hepatitis B virus infection

This study uses time-resolved proteomics to analyze host protein changes during early HBV infection, revealing coordinated proteome alterations and specific complement pathway dynamics.

Promyelocytic leukemia (PML) suppresses hepatitis B virus cccDNA transcription through SUMOylation- and SMC5/6-dependent mechanisms

This study shows PML suppresses HBV cccDNA transcription via SUMOylation and SMC5/6-dependent mechanisms, with HBx modulating this interaction.

Genetic accessibility, not superior fitness, determines which anti-HBs antibody escape variants are selected in patients

This study identifies that genetic accessibility, not superior fitness, determines the selection of anti-HBs antibody escape variants in patients using in vivo screening.

Serum IgM crosslinks hepatitis B subviral particles into supramolecular immune complexes

The paper uses cryo-ET to show serum IgM crosslinks HBV SVPs into supramolecular immune complexes through multivalent Fab interactions.

The HBV basal core promoter mutation confers a replicative advantage and transcriptionally reprograms hepatocytes toward HCC subtypes

This study shows that HBV BCP mutations enhance viral replication and alter hepatocyte transcription, linking to specific HCC subtypes.

Hepatitis B virus proteome analysis identifies apolipoprotein C1 facilitating particle production and virus entry

The paper identifies apolipoprotein C1 as a host factor that facilitates HBV and HDV infection by associating with viral particles and enhancing infectivity through SR-B1.

RNAi-mediated HBV antigen shutdown enhances the antiviral immune effects of PEGIFNalpha via altering T and B cell crosstalk

This study shows that combining RNAi-mediated HBV antigen shutdown with PEGIFNalpha enhances antiviral immunity by improving T and B cell interactions and function in a mouse model of chronic hepatitis B.

Residue-level predictions of the protein-protein interactions of the hepatitis B virus core and envelope proteins

The paper predicts residue-level protein-protein interactions between hepatitis B virus core and envelope proteins using deep learning and coevolution signatures, comparing results with experimental data.

Infection of neotropical non-human primates with bat deltaviruses

This study detects deltaviruses in neotropical non-human primates and finds phylogenetic links to vampire bats, suggesting cross-order host shifts and a zoonotic origin for hepatitis D virus.

Precision-cut liver slices as a model for evaluating therapeutic agents against hepatitis B and delta viruses

This study evaluates precision-cut liver slices as an ex vivo model for studying HBV/HDV co-infection and testing antiviral agents.

Vorapaxar and aripiprazole suppress hepatitis B virus replication through distinct host signaling pathways

This paper identifies vorapaxar and aripiprazole as inhibitors of HBV replication through distinct host signaling pathways, showing their potential as host-targeting antivirals.

E3 ubiquitin ligase HUWE1 mediates K6-linked polyubiquitylation and stabilization of Nrf2 to restrict hepatitis B virus replication

ddOTs: a multiplexed quantitative ddPCR approach for resolving overlapping hepatitis B virus transcripts to decipher cccDNA-driven transcription

The paper introduces ddOTs, a ddPCR method to quantify overlapping HBV transcripts, enabling precise analysis of cccDNA-driven transcription and RNA stability.

Therapeutic Potential of the Novel Monoclonal Antibody 7-4G against HBsAg in a Mouse Model of Chronic Hepatitis B Virus Infection

This study evaluates the antiviral activity of the monoclonal antibody 7-4G against HBsAg in a mouse model of chronic HBV infection, showing significant reduction in viral markers.

Orthogonal CRISPR screens and human liver chimeric mice identify hepatitis B virus host factors

The paper identifies HBV host factors using CRISPR screens and human liver chimeric mice, finding that EXOC1 is antiviral and ZCCHC14 is proviral.

PML nuclear bodies orchestrate the storage and degradation of aggregated HBc in the nucleus and reduce CAM-A-induced apoptosis.

This study shows that PML nuclear bodies store and degrade aggregated HBc, reducing apoptosis caused by CAM-A.

CD8 T cells with classical and NK-like cytotoxic gene expression programs mediate control of HBV replication and functional cure

The paper identifies two distinct CD8 T cell gene expression programs in HBV infection that correlate with viral control and functional cure.

Hepatitis B virus protein X promotes hepatocyte plasticity and survival in a differentiated human liver organoid system

This paper shows HBx promotes hepatocyte survival and reduces differentiation in human liver organoids, potentially contributing to liver cancer.

Reversal effects of Isochlorogenic acid A on HBV-induced transcriptional dysregulation and apoptotic signaling

This study investigates how ICAA affects HBV-induced gene expression and apoptotic signaling in HepAD38 cells, finding it reverses transcriptional dysregulation and promotes apoptosis.

Reconciling fast Hepatitis B evolutionary rates with ancient co-divergence

This study uses a Bayesian mixed-effects molecular clock model to analyze HBV genomic data, revealing declining evolutionary rates and linking viral spread to human migration patterns.

Preserved CD4+ T cell helper function and coordinated antiviral immunity in people with HBV/HIV co-infection on long-term therapy

This study shows that people with HBV/HIV co-infection maintain functional HBV-specific CD4+ T helper responses and coordinated CD4/CD8 antiviral immunity, suggesting preserved antiviral immunity.

Preclinical antiviral study of a liver-targeted TLR1/2 agonist in an immune-competent mouse model of HBV infection

This study evaluates a liver-targeted TLR1/2 agonist nanoparticle formulation for HBV treatment, showing enhanced antiviral effects compared to free agonist in mice.

Modeling Reveals How Direct-Acting Antivirals Redirect HBV Capsid Assembly Pathways to Noninfectious Products

The paper uses a kinetic Monte Carlo model to simulate how CAMs alter HBV capsid assembly, revealing mechanisms that lead to noninfectious structures.

Hepatitis B virus HBx protein masks epigenetic reader Spindlin1 via an inter-molecular zinc finger to subvert transcriptional control

This study identifies how HBx protein interacts with Spindlin1 via a zinc finger to disrupt epigenetic control and promote viral DNA transcription.

Scavenger Receptor class F member 2 is an intracellular receptor for Hepatitis B virus

This study identifies SCARF2 as an intracellular receptor for HBV, showing it facilitates viral transport to the nucleus by binding preS1 and interacting with nuclear pore complexes.

Assembly-active and -inactive forms of HBV capsid protein provide distinctly different binding sites for capsid assembly modulators

This study compares the binding of CAMs to two forms of HBV capsid protein, showing structural differences in CAM site adaptation between assembly-active and -inactive forms.

Identification of Cyclin L1 as a host factor regulating Hepatitis B Virus replication

This study identifies Cyclin L1 as a host factor that regulates Hepatitis B Virus replication by modulating RNA Polymerase II phosphorylation and activity.

Multiplex Gene Editing Suppresses Random Integration of Hepatitis B Virus DNA in Chronically Infected Liver

This study uses CRISPR-Cas9 to reduce HBV DNA in infected cells, showing it suppresses random integration without affecting chromosomal translocations.

Structural and Functional Insights into HBx-Smc6 Targeting for HBV Inhibition

This study determines the structure of the HBx-CRL4-Smc5/6 complex and identifies a druggable interface for antiviral therapy against HBV.